These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 3890399)

  • 1. Immunopotentiating conjugates.
    Stewart-Tull DE
    Vaccine; 1985 Mar; 3(1):40-4. PubMed ID: 3890399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of T cell anergy in leprosy patients: in vitro presentation with Mycobacterium leprae antigens using murabutide and Trat peptide in liposomal delivery.
    Sridevi K; Khanna N; Chattree V; Pal PC; Haq W; Rao DN
    Int Immunopharmacol; 2003 Nov; 3(12):1589-600. PubMed ID: 14555284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomes as carriers of antigens and adjuvants.
    Alving CR
    J Immunol Methods; 1991 Jun; 140(1):1-13. PubMed ID: 1712030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status of immunological adjuvants.
    Warren HS; Vogel FR; Chedid LA
    Annu Rev Immunol; 1986; 4():369-88. PubMed ID: 2871847
    [No Abstract]   [Full Text] [Related]  

  • 5. Epitope specific immunity elicited by totally synthetic monovalent or polyvalent vaccines.
    Chedid L; Audibert F; Jolivet M; Carelli C; Uzan M; Gras-Masse H; Tarter A
    Ann Sclavo Collana Monogr; 1984; 1(2):77-85. PubMed ID: 6400358
    [No Abstract]   [Full Text] [Related]  

  • 6. Role of muramyl peptides for the enhancement of synthetic vaccines.
    Chedid L; Audibert F; Jolivet M
    Dev Biol Stand; 1986; 63():133-40. PubMed ID: 3527818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomes, muramyl dipeptide derivatives, and nontoxic lipid A derivatives as adjuvants for human malaria vaccines.
    Hui GS
    Am J Trop Med Hyg; 1994; 50(4 Suppl):41-51. PubMed ID: 8172331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The immunopotentiating property of lipophilic muramyl dipeptide and its molecular state in liposomal membranes: plaque-forming cell responses and ESR studies.
    Manabe H; Utsumi H; Kusama T; Hamada A
    J Biochem; 1989 Jun; 105(6):861-3. PubMed ID: 2549019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunoadjuvant activities of bacterial cell wall components--with special reference to the effects of administration with various vehicles].
    Kinoshita F
    Osaka Daigaku Shigaku Zasshi; 1978 Jun; 23(1):141-57. PubMed ID: 397324
    [No Abstract]   [Full Text] [Related]  

  • 10. Adjuvant formulations and their mode of action.
    Allison AC; Byars NE
    Semin Immunol; 1990 Sep; 2(5):369-74. PubMed ID: 1966859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New technology of vaccine production--international prospect of the development. Development of synthetic immunologic adjuvants and MDP-antigen binding vaccines].
    Azuma I
    Nihon Rinsho; 1987 Oct; 45(10):2355-61. PubMed ID: 3448269
    [No Abstract]   [Full Text] [Related]  

  • 12. [Antitumor immunoadjuvants of microbial origin: the limitations in the immune system and microbial structure].
    Cassone A
    Ann Ist Super Sanita; 1982; 18(3):497-500. PubMed ID: 6765082
    [No Abstract]   [Full Text] [Related]  

  • 13. [Stimulation of polymorphonuclear leukocytes by bacterial cell wall components and related synthetic compounds].
    Ishihara Y
    J Osaka Univ Dent Sch; 1981 Jun; 26(1):105-20. PubMed ID: 6945420
    [No Abstract]   [Full Text] [Related]  

  • 14. Novel vaccination strategies for the control of mucosal infection.
    Husband AJ
    Vaccine; 1993; 11(2):107-12. PubMed ID: 8438609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent developments concerning muramyl dipeptide, a synthetic immunoregulating molecule.
    Chedid L; Carelli C; Audibert F
    J Reticuloendothel Soc; 1979 Dec; 26(Suppl):631-41. PubMed ID: 392087
    [No Abstract]   [Full Text] [Related]  

  • 16. Activation of Kupffer cell tumoricidal activity by immunomodulators encapsulated in liposomes.
    Daemen T
    Res Immunol; 1992 Feb; 143(2):211-4. PubMed ID: 1574650
    [No Abstract]   [Full Text] [Related]  

  • 17. Lipophilic Muramyl Dipeptide-Antigen Conjugates as Immunostimulating Agents.
    Willems MM; Zom GG; Meeuwenoord N; Khan S; Ossendorp F; Overkleeft HS; van der Marel GA; Filippov DV; Codée JD
    ChemMedChem; 2016 Jan; 11(2):190-8. PubMed ID: 26059481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developing subunit immunogens using B and T cell epitopes and their constructs derived from the F1 antigen of Yersinia pestis using novel delivery vehicles.
    Sabhnani L; Manocha M; Sridevi K; Shashikiran D; Rayanade R; Rao DN
    FEMS Immunol Med Microbiol; 2003 Oct; 38(3):215-29. PubMed ID: 14522457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developmental status of synthetic immunomodulators.
    Berendt MJ; Ives JL
    Year Immunol; 1985; ():193-201. PubMed ID: 2437723
    [No Abstract]   [Full Text] [Related]  

  • 20. Cationic liposomes as vaccine adjuvants.
    Christensen D; Korsholm KS; Rosenkrands I; Lindenstrøm T; Andersen P; Agger EM
    Expert Rev Vaccines; 2007 Oct; 6(5):785-96. PubMed ID: 17931158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.